Biomarkers for alzheimer's disease progression
A technology for Alzheimer's disease and disease, applied in biological testing, biomaterial analysis, drug combination, etc., can solve problems that cannot be cured and the etiology is not fully known
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0159] Example 1. AFFYMETRIX 100K Genome Scan in Patients from the InDDEx Trial
[0160] [156] Introduction and Overview. The purpose of this example is to describe a genetic association study that identified 25 AD-associated mutations of the invention. Genome-wide analysis for genetic association studies has only become possible in the past two years. The Investigational Study of Delaying a Diagnosis of Alzheimer's Disease Using Exelon (InDDex; ENA713B IA07) clinical trial followed patients with MCI and administered either different doses of Exelon (rivastigmine) or placebo. agent and track its conversion to AD. The trial optionally had a DNA collection component, in which 442 samples were collected.
[0161] [157] To identify genetic variants that drive the conversion of MCI to AD, 420 patient samples from the InDDex (ENA713B IA07) clinical trial were analyzed using Haploview's case-control assay using the Affymetrix 100K gene assay at single loci and putative haplotype b...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com